文献速递基础与转化研究临床试验与 GCP组学、生物样本库与精准医学

头颈癌放疗后唾液分泌减少患者腺体内间充质基质细胞治疗后唾液蛋白质组探索:MESRIX-III随机对照试验的二次研究方案

Exploring the salivary proteome following intraglandular mesenchymal stromal cell therapy for radiation-induced hyposalivation in previous head and neck cancer patients: a secondary study protocol for the MESRIX-III, randomised, controlled trial.
PubMed 文献 · Trials · 2025-11-28

本研究为MESRIX-III随机双盲安慰剂对照试验的二次研究方案,纳入120例既往头颈癌放疗后唾液分泌减少患者,按1:1随机接受腺体内注射同种异体脂肪来源间充质基质细胞(ASC)或安慰剂。主要终点为4个月时ASC组与安慰剂组唾液人类蛋白质组的质谱分析比较,次要终点包括微生物蛋白质组比较及组内变化。

要点

  • MESRIX-III试验纳入120例放疗后唾液分泌减少的头颈癌患者,1:1随机接受ASC或安慰剂腺体内注射。
  • 主要终点为4个月时ASC组与安慰剂组未刺激全唾液人类蛋白质组的质谱分析比较。
  • 次要终点包括微生物蛋白质组比较、ASC组基线与4个月变化及两组基线放疗后蛋白质组评估。

核心结论

  • 本研究旨在深入理解腺体内ASC治疗放疗诱导唾液分泌减少的潜在作用机制。
  • 结果可能为改善头颈癌患者放疗后唾液分泌减少和恢复唾液腺功能开辟临床应用及疾病修饰治疗途径。
  • 本研究将构成头颈部放疗后唾液蛋白质组特征描述的最广泛数据集合。

研究设计与样本

  • 本研究为MESRIX-III随机双盲安慰剂对照试验的二次研究方案。
  • 共纳入120例既往头颈癌放疗后唾液分泌减少患者,按1:1比例随机接受腺体内注射同种异体ASC或安慰剂(CryoStor10,含10%二甲基亚砜,Biolife Solutions)。
  • 在基线和移植后4个月收集未刺激全唾液样本。

关键数值与推荐

  • 主要终点为4个月时ASC组与安慰剂组唾液人类蛋白质组的质谱分析比较。
  • 次要终点包括4个月时ASC组与安慰剂组微生物蛋白质组的比较。
  • 次要终点包括ASC组从基线至4个月唾液蛋白质组和微生物蛋白质组的变化。
  • 次要终点包括两组基线时放疗后唾液蛋白质组和微生物蛋白质组的评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intraglandular therapy with adipose-derived mesenchymal stromal cells (ASCs) for radiation-induced xerostomia and hyposalivation has shown promising effects on the salivary flow rate and in patient-reported outcomes. However, the mode of action is not fully understood, but changes in the salivary proteome have been observed. METHODS: This sub study, to the randomised, double-blinded, placebo-controlled trial investigating intraglandular mesenchymal stromal cells for radiation-induced hyposalivation (MESRIX-III), examines changes in the salivary proteome following intraglandular therapy into the submandibular glands with allogenic ASCs in unstimulated whole saliva (UWS) in previous head and neck cancer patients with radiation-induced hyposalivation. A total of 120 patients were included and randomised in a 1:1 ratio to receive intraglandular injections with either ASCs or placebo (CryoStor10, 10% dimethyl sulfoxide, Biolife Solutions). UWS samples was collected at baseline and at 4 months post transplantation. The main endpoint is comparison of the salivary human proteome evaluated by mass spectrometry analysis in the group receiving ASCs compared to placebo at 4 months. Secondary outcomes are comparison of the microbial proteome in the group receiving ASCs compared to placebo at 4 months; changes in the salivary proteome and microbial proteome in the group receiving ASCs from baseline to 4 months and evaluation of the salivary proteome and microbial proteome following radiation therapy at baseline in both groups. DISCUSSION: This study will gain insights into the potential mode of action of intraglandular ASC therapy for radiation-induced hyposalivation. The results may open avenues for a clinically applicable and disease-modifying treatment to ameliorate hyposalivation and restore salivary gland function following radiation therapy in previous head and neck cancer patients. Moreover, it will constitute the most extensive collection of data characterising the salivary proteome post-radiation therapy in the head and neck region. TRIAL REGISTRATION: The MESRIX-III study is approved by the Danish Data Protection Agency (protocol number P-2020-1164), the National Ethics Committee (protocol number: 1802872) and the Danish Medical Agency (2018-000348-24) and is registered at the ClinicalTrials.gov database (NCT04776538). First posted on clinicaltrials.gov 03-JAN-2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Carlander AF, Jakobsen KK, Jersie-Christensen R, et al. Exploring the salivary proteome following intraglandular mesenchymal stromal cell therapy for radiation-induced hyposalivation in previous head and neck cancer patients: a secondary study protocol for the MESRIX-III, randomised, controlled trial. Trials. 2025. PMID: 41316394. doi:10.1186/s13063-025-09074-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。